Pharmacogenomics: Precision Pharmacy in 503A Compounding
Author(s): Drummond Joseph, Bennet Daron, Allen Loyd V Jr
Issue: Mar/Apr 2018 - Volume 22, Number 2
View All Articles in Issue
Page(s): 95-107
Download in electronic PDF format for $75
Abstract: The first recorded mention of a pharmacogenomic response may be that of Pythagoras in 510 BC, when he noted that hemolytic anemia developed in some but not all people who ingested fava beans. The application of such accounts to pharmacotherapy was inevitable, and customized medications have been compounded since antiquity to treat the needs of individual patients. Today, advances in pharmacogenomic testing yield results that enable more effective targeted therapies sooner in the course of treatment, prevent drug-related adverse effects, save cost, and ensure a better therapeutic outcome. The value of such testing is now more widely accepted, even in the public domain. It is our opinion that third-party payors will realize, to an increasing degree, that this new technology will save them money and will pay for it. Because independent compounding pharmacists have trusted relationships with patients and are convenient to visit, they are well placed to offer certain types of pharmacogenomic tests to patients and prescribers. In this article, topics that we address include the difference between pharmacogenomics and pharmacogenetics; the use of pharmacogenomic testing in 503A compounding; the benefits of such tests for patients, prescribers, and compounders; and suggestions for marketing pharmacogenomics testing. Information about a course that introduces pharmacogenomic science to compounders is provided, and suggestions for additional reading and other resources about pharmacogenomic testing are included for easy reference.
Related Keywords:
Joseph Drummond, PharmD, Daron Bennet, Loyd V. Allen Jr., PhD, RPh, precision medicine, customized medications, personalized medicine, pharmacogenomic testing, pharmacogenetics, continuing education, drug-gene interactions, drug-drug interactions, drug-lifestyle interactions, drug safety, adverse effects, side effects
Related Categories:
BUSINESS, MARKETING, TECHNOLOGY, PATIENT ASSESSMENT, PROFESSIONAL ISSUES, INFORMATION RESOURCES
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Pharmacogenomics: Precision Pharmacy in 503A Compounding
Drummond Joseph, Bennet Daron, Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 95-107
|
Veterinary Transdermal Medications: A to Z
Davidson Gigi S
|
Mar/Apr 2003
Pg. 106-113
|
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun
|
Mar/Apr 2018
Pg. 108-121
|
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
|
Nov/Dec 2003
Pg. 449-450
|
Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula
Hossain Mohammad Faisal, Levesque Dan, Frye John, Rashid Mamoon
|
Jul/Aug 2020
Pg. 322-326
|
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies
Pritchett Jon, McCrory Gary, Kraemer Cheri, Jensen Brenda, Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 7-16
|
Pharmacogenomics as a Competitive Strategy for Compounding Pharmacies
Maham Nicole Y
|
Nov/Dec 2022
Pg. 474-479
|
Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2
Allen Loyd V
|
Jul/Aug 2015
Pg. 280-287
|
Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
|
Sep/Oct 2020
Pg. 356
|
The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, LlambĂ Francesc
|
Jan/Feb 2014
Pg. 6-12
|
Pharmacogenomics: The End of Trial-and-Error Medicine?
Vail Jane
|
Jan/Feb 2007
Pg. 59-65
|
Microbiologic Testing for 503A Sterile-Compounding Pharmacies
Mixon William, Roth Abby
|
May/Jun 2017
Pg. 193-203
|
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
|
Mar/Apr 2017
Pg. 95-102
|
Utilization of Compounded Medications in an Oral Medicine Practice
Stock Shannon, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
|
Mar/Apr 2016
Pg. 155-158
|
Pharmaceutical Compounding: The Oldest, Most Symbolic, and Still Vital Part of Pharmacy
Kochanowska-Karamyan Anna J
|
Sep/Oct 2016
Pg. 367-374
|
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Blankenship Cynthia E
|
Sep/Oct 2014
Pg. 379-380
|
Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R, Newton Gail D
|
May/Jun 2004
Pg. 181-185
|
Quality Control Analytical Methods: End-preparation Assessments and Tests for Compounded Sterile Preparations
McElhiney Linda F
|
Jul/Aug 2013
Pg. 307-311
|
Performance Improvement in 503A Compounding Pharmacies: A Plan for Assessment, Implementation, and Sustained Success
Pritchett Jon, Mixon William, O'Connell Kevin
|
Jan/Feb 2016
Pg. 29-36
|
Basics of Sterile Compounding: Intravenous Admixture Preparation, Part 12: United States Pharmacopeia Chapters Referenced in the Current United States Pharmacopeia Chapter <797> Pharmaceutical Compounding -- Sterile Preparations
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 491-496
|
Return to Top |